Online Program

The online program of the NRM 2021 will be available here soon.

The following Link will forward you to the tentative online program of the NRM 2021.

Keynote Speaker

Nicola Palomero-Gallagher

Nicola Palomero-Gallagher, PhD, PD, graduated 1990 from the Sciences Faculty of the Universidad Autónoma of Madrid, Spain. She was a PhD student at the C. & O. Vogt-Brain Research Institute of the Heinrich-Heine University Düsseldorf, Germany, between 1992 and 1999, and received the PhD in 1999. Since 2000 she works at the Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Germany, where she is a Senior Researcher and Leader of the research group “Rezeptoren”. She is a senior editor of Brain Structure and Function. Her research is centered on the structural (cyto- and fiber-architecture) and molecular (receptor-architecture) organization of the human, non-human primate and rodent cerebral cortex, with particular focus on the cingulate cortex. Her major goal is to understand the cyto- and receptor-architectonic basis of cortical segregation and interareal interactions, with emphasis on their relationship with function.

Marc Diamond

Director, Center for Alzheimer’s and Neurodegenerative Diseases, UT Southwestern Medical Center

Marc Diamond, M.D., is the founding director of the Center for Alzheimer’s and Neurodegenerative Diseases and is a professor of neurology and neurotherapeutics. Dr. Diamond completed an internship, residency and chief residency in neurology at the University of California, San Francisco (UCSF) in 1997. After a postdoctoral fellowship, he was a faculty member in the Neurology Department at UCSF from 2002–2009. From 2009–2014, he was the David Clayson Professor of Neurology at Washington University in St. Louis, before he was recruited to UT Southwestern. His research focuses on molecular mechanisms of neurodegeneration in Alzheimer’s disease and related disorders, with the goal of developing novel therapies and diagnostic tools. A therapeutic antibody he co-developed at Washington University in St. Louis is now entering clinical trials for treatment of dementia. The Center for Alzheimer’s and Neurodegenerative Diseases is comprised of a multidisciplinary group of investigators who are focused on understanding the basis of progressive protein aggregation in human disease. They are using this knowledge to hasten the day when neurodegeneration can be detected pre-symptomatically and stopped before it causes disability.

Michael Heneka

Cooperation Unit Leader, Neuroinflammation, German Center for Neurodegenerative Diseases

Dr. Heneka completed his doctoral degree in the Department of Pharmacology and Toxicology at the University of Tübingen in Germany and his habilitation at the University of Bonn. He is currently Cooperation Unit Leader, Neuroinflammation, at the German Center for Neurodegenerative Diseases (DZNE) in Bonn, adjunct professor at the University of Massachusetts Medical School in Worcester, Massachusetts, and a professor and director of the Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology at the University of Bonn. The Heneka laboratory studies the interaction between innate and adaptive immunity and the central nervous system using novel preclinical mouse models and state-of-the-art techniques such as two-photon in vivo laser scanning microscopy, optogenetics, transcriptome analysis, and induced pluripotent stem cells (iPSCs). Major diseases studied include Alzheimer’s disease, amyotrophic lateral sclerosis, septic encephalopathy, and multiple sclerosis, with the goal of developing new biomarkers and medical intervention programs.